GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

Some consumers take tiny doses of Ozempic and other GLP-1 drugs or stretch out doses to cut costs and side effects.

Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...

The U.S. Environmental Protection Agency has drafted a plan to eliminate all limits on greenhouse gases from coal and ...

The U.S. Food and Drug Administration has cracked down on compounded drugs, which were readily available while the patented ...

Eli Lilly & Co. said Tuesday it’s cutting the ... a regulatory ruling that there’s no longer a shortage of weight-loss drugs that had allowed for alternatives to be made, sending the stock ...

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending ...

The Cigna Group (NYSE: CI )’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.